NCT05657691 - Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) | Biotech Hunter

Enrollment

167

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Major Depressive DisorderMDDCognitive Impairment

Interventions

DRUG

Xanamem™

Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.

DRUG

Placebo

Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.

Trial Locations (12)

3004

Ramsay Clinic Albert Road, Melbourne

Unknown

Paratus Clinical Research Western Sydney, Blacktown

Genesis Research Services, Newcastle

Paratus Clinical Research Brisbane, Brisbane

USC Clinical Trials, Sippy Downs

Monash Alfred Psychiatry Research Centre, Melbourne

NeuroCentrix, Noble Park

EC2Y 8EA

St Pancras Clinical Research, London

W1G 8DR

Clerkenwell Health, London

M13 9NQ

MAC Clinical Research - Manchester, Manchester

ML1 4UF

Glasgow Memory Clinic, Motherwell

S75 3DL

MAC Clinical Research - South Yorkshire, Tankersley